Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof
This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
1. An isolated nucleic acid encoding an anti-IL-17F antibody heavy chain variable region and/or light chain variable region, or an antigen-binding fragment thereof, wherein said antibody comprises:
(a) a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 45;
(b) a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46;
(c) a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47;
(d) a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 74;
(e) a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75; and
(f) a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76.
2. The nucleic acid of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 10 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 12 or 103.
3. The nucleic acid of claim 1 , wherein the nucleic acid encodes the heavy chain variable region and the light chain variable region.
4. The nucleic acid of claim 3 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:10, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:12.
5. The nucleic acid of any one of claims 1 - 4 , wherein said antibody, or antigen-binding fragment, does not bind the IL-17A homodimer.
6. The nucleic acid of any one of claims 1 - 4 , wherein said antibody, or antigen-binding fragment, is an IgG isotype.
7. The nucleic acid of claim 6 , wherein said antibody, or antigen-binding fragment, is an IgG1 isotype.
8. An isolated recombinant host cell transformed with the nucleic acid of any one of claims 1 - 4 .
9. A vector comprising the nucleic acid of claim 1 or claim 2 .
10. A vector comprising the nucleic acid of claim 3 or claim 4 .
11. An isolated recombinant host cell transformed with the vector of claim 10 .
12. A method of making an anti-IL-17F antibody encoded by the nucleic acid in the vector of claim 10 , or an antigen-binding fragment thereof, said method comprising culturing a recombinant host cell transformed with the vector in a culture medium to express said anti-IL-17F antibody or antigen-binding fragment.
13. A method of making an anti-IL-17F antibody encoded by the nucleic acid of claim 3 or 4 , or an antigen-binding fragment thereof, said method comprising culturing a recombinant host cell transformed with the nucleic acid in a culture medium to express said anti-IL-17F antibody or antigen-binding fragment.